Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-AlF-NOTA-neurotensin
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
**18F-AlF-NOTA-neurotensin** is a radiolabeled peptide-based PET imaging agent designed to target neurotensin receptor 1 (NTR1). It consists of a neurotensin analog conjugated to the chelator NOTA, which is labeled with aluminum-fluorine-18 ([18F]AlF) via a simple chelation method. This probe binds with high affinity and specificity to NTR1, which is overexpressed in several cancers, notably pancreatic ductal adenocarcinoma. Preclinical studies have demonstrated its ability to provide high tumor-to-background contrast in PET imaging of NTR1-positive tumors. The agent may be used for noninvasive detection and characterization of NTR1-expressing tumors and has potential theranostic applications by enabling patient selection for targeted therapies[2][1].
- Other names
- [18F]AlF-NOTA-NT18F-labeled NOTA-neurotensinaluminum-[18F]-fluoride NOTA-neurotensin
02
Targets
NTR1 (Nitroreductase-1)
Beyond the preview
Go deeper on 18F-AlF-NOTA-neurotensin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-AlF-NOTA-neurotensin.